SEER

SEER INC

Healthcare | Micro Cap

-$0.17

EPS Forecast

$4.62

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Seer, Inc. (SEER) Quietly Grows Revenue Forecast as Proteomics Pushes Ahead of ITC Hurdles

In the world of high-tech biology, a stumble toward profitability is still a win if you’re growing revenue and shoring up the balance sheet. Seer, Inc. (SEER) released its third-quarter 2026 update with a tidy revenue beat and a raised revenue forecast, while navigating an ongoing ITC-related legal drift. No EPS figure jumped out of the press release, but the earnings-per-share story here, if it materializes at all, remains a longer game. For now, the focus sits squarely on revenue growth, cash runway, and strategic independence.

Financial snapshot: revenue growth, not profits, in sight

Seer reported third-quarter revenue of $4.0 million, up from $3.1 million in the prior quarter. The company closed the quarter with roughly $198.1 million in cash, cash equivalents and investments, providing a sizable cushion as it funds R&D and go-to-market efforts tied to its Proteograph platform.

Looking ahead, Seer updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million, nudging the midpoint higher as the quarter underscored ongoing demand for its products. The press release does not publish an EPS figure, and there was no explicit earnings surprise announced in conjunction with this quarterly update. In this narrative, the EPS consensus remains a moving target that investors will expect to resolve once profitability is on the agenda rather than merely a revenue milestone.

Management view: growth-readiness and a shielded balance sheet

Omid Farokhzad, Chair and Chief Executive Officer, framed the quarter as a validation of Proteograph’s ability to unlock new discoveries at scale. He emphasized the platform’s role in expanding the biology researchers can observe with mass spectrometry, while the company focuses on translating that differentiated value into sustained revenue growth. The emphasis on expanding sample volume within customer accounts suggests a strategy oriented toward repeat use and increased wallet share, rather than a one-off sale cadence.

Corporate highlights: governance, independence, and industry tailwinds

Two corporate developments deserve attention. First, Seer confirmed that, on October 29, the Special Committee of its Board completed its review and reaffirmed Seer’s status as an independent public company, reinforcing the governance framework around strategic decisions. Second, a November 5 update noted that Nanomics Biotechnology Co., Ltd. withdrew from defending a U.S. International Trade Commission investigation brought by Seer and Brigham and Women’s Hospital. The ITC staff has recommended granting the full exclusion and cease-and-desist orders requested by the Commission, with a final determination expected by year-end. These regulatory dynamics could shape both near-term risk and mid-term competitive positioning for Seer and peers in the proteomics ecosystem.

Scientific highlights: publishing momentum and a bigger plasma proteome

Seer highlighted that publications, preprints and reviews describing research using Proteograph reached 116, up from 95 in the prior quarterly update, signaling strong engagement across the research community. In a more technical note, PRECISE-SG100K investigators presented preliminary HUPO 2026 findings from 9,658 plasma samples, quantifying roughly 8,800 protein groups across the study and about 88,000 peptides per sample when Proteograph is used with Thermo Fisher’s Orbitrap Astral mass spectrometer.

Additionally, Seer’s Proteograph nanoparticle enrichment is described as substantially expanding the plasma proteome available for discovery. Across published studies and customer presentations, the company asserts that conventional mass spectrometry workflows without Proteograph achieve only a fraction of the protein coverage attained with its technology. If the trend lines hold, the scientific momentum could translate into stronger demand pull as researchers pursue larger, more complex studies.

Outlook: what this means for SEER and the sector

The quarterly update reinforces a narrative of early-stage revenue growth funded by a robust balance sheet. The raised revenue forecast points to continued adoption of Proteograph within both academic and pharmaceutical settings, including large pharmaceutical customers, which Seer notes as a meaningful source of repeat purchases and broader use within existing accounts.

From a market structure perspective, the ITC proceedings and the board’s reaffirmation of independence matter. Regulators’ actions and outcomes can affect investor sentiment and entry/exit dynamics for peers navigating similar trade issues or competitive tensions with assay providers and instrument manufacturers. For SEER and its sector peers, the path forward appears to hinge on scale: converting early wins into durable, multi-quarter revenue streams while managing regulatory and competitive risk.

Notes on the earnings narrative

  • Ticker and coverage: SEER remains in focus as a specialty proteomics player whose business model hinges on multi-quarter adoption cycles rather than rapid mass-market penetration.
  • EPS and EPS consensus: The press release does not report EPS, and there is no explicit EPS consensus provided. Investors will likely watch for future profitability milestones to cross the EPS threshold, or for a path toward positive earnings per share as revenue scales and cost discipline improves.
  • Revenue forecast: The raised revenue guidance signals continued demand for Proteograph and related consumables, but the narrative remains centered on revenue growth rather than profitability in the near term.
  • Earnings surprise: No earnings surprise is reported in this release. The emphasis is on top-line progression and strategic milestones rather than quarterly earnings surprises.
  • Risks to watch: ITC developments, governance decisions around independence, and the broader regulatory environment could influence near-term volatility and investor sentiment.

Conclusion: a growth story with a long horizon

Seer’s Q3 2026 update reads like a company that has chosen growth as its operating system, with a sizeable cash runway and a clear emphasis on expanding the Proteograph user base and throughput. The raised revenue forecast provides a practical signal that market demand for proteomics instrumentation and consumables remains resilient, even as the business navigates regulatory headwinds and a multi-quarter path to profitability.

For sector peers, the key takeaway is that early momentum in scientific adoption—paired with governance clarity and regulatory risk management—can sustain a narrative of long-term value creation even when near-term earnings per share still have to prove themselves. In a field where discoveries translate into funding cycles and collaboration opportunities, Seer’s trajectory offers a blueprint for balancing science with strategic restraint.

Note: All figures are as reported for the quarter ended September 30, 2026, unless otherwise stated. This article aims to interpret the disclosed information and provide a forward view on potential implications for SEER and the proteomics ecosystem.